Selected Publications by Core Users

2006

+          Gore L (DT), Holden SN (DT), Cohen RB, Morrow M, Pierson AS, O'Bryant CL, Persky M,   Gustafson D (DT), Mikule C, Zhang S, Palmer PA, Eckhardt SG (DT).  A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.  Ann Oncol 17(11):1709-1717, 2006.

*+        Guo W, Reigan P, Siegel D (CC), Zirrolli J, Gustafson D (DT), Ross D (CC,DT).  The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 (NQO1) to more potent heat shock protein 90 (Hsp90) inhibitors, the hydroquinone ansamycins.  Mol Pharmacol 70(4):1194-1203, 2006.

*+        Helfrich BA, Raben D (TOP,DT), Varella-Garcia M (TOP), Gustafson D (DT), Chan DC (DT,TOP), Bemis L (CC), Coldren C (TOP), Baron A (DT), Zeng C, Franklin W (TOP), Hirsch FR (TOP,DT), Gazdar A, Minna J, Bunn PA Jr (TOP).  Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.  Clin Cancer Res 12(23):7117-7125, 2006.

2007

+          Bradshaw-Pierce EL, Eckhardt SG (DT), Gustafson DL (DT).  A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.  Clin Cancer Res 13(9):2768-2776, 2007.

*+        Flaig TW (DT), Gustafson DL (DT), Su LJ, Zirrolli JA, Crighton F, Harrison GS (CB), Pierson AS, Agarwal R (HRM,CC), Glode LM (HRM).  A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.  Invest New Drugs 25(2):139-146, 2007.

*           Gustafson DL (DT), Frederick B, Merz AL, Raben D (TOP,DT).  Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima((R))) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.  Cancer Chemother Pharmacol , in press, 2007.

+          Hariharan S, Gustafson D (DT), Holden S (DT), McConkey D, Davis D, Morrow M, Basche M (DT), Gore L (DT), Zang C, O'Bryant C, Barón A (DT), Gallemann D, Colevas D, Eckhardt S (DT).  Assessment of the biological and pharmacological effects of the {alpha}{nu}{beta}3 and {alpha}{nu}{beta}5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.  Ann Oncol 18(8):1400-1407, 2007.

*           Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D (DT), Morley P, Dow S (II).  Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.  J Vet Intern Med 21(4):764-769, 2007.

+          Troiani T, Serkova NJ (DT), Gustafson DL (DT), Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG (DT).  Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signaling, in combination with irinotecan in a human colon cancer xenograft model.  Clin Cancer Res, in press, 2007.

+          Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL (DT), Anchordoquy TJ (DT).  In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: Effects on biodistribution and tumor accumulation.  J Pharm Sci, in press, 2007.